Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 55Gastrointestinal 34Thoracic 31CNS 27Breast 15Tumor-Agnostic 9Dermatologic 9Head & Neck 8Sarcoma 4NET 2Gynecologic 2Endocrine 2Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasm Metastasis 1Lymphoma 1

Interventions

Cyclophosphamide 174Rituximab 146venetoclax 82Specimen Handling 81fludarabine 80Vincristine 69obinutuzumab 68Prednisone 66Doxorubicin 66Biopsy 63Magnetic Resonance Spectroscopy 62Lenalidomide 54zanubrutinib 52Dexamethasone 48Cytarabine 44Methotrexate 43blinatumomab 41Immunotherapy, Adoptive 40acalabrutinib 37Bendamustine Hydrochloride 37fludarabine phosphate 32Etoposide 32ibrutinib 30polatuzumab vedotin 27glofitamab 27pirtobrutinib 25orelabrutinib 25Gemcitabine 24Injections 21Mercaptopurine 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Radiosurgery × Lymphoid × Clear all
NCT05371132 2026-01-28

Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)

City of Hope Medical Center

Phase 1 Recruiting
10 enrolled
Lymphoid

Lymphoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡